Please login to the form below

Not currently logged in
Email:
Password:

Stephen Eck joins Aravive Biologics

He takes up president and CEO positions

Aravive Biologics has appointed Stephen Eck as its new CEO and president at a time when the company is preparing to advance its lead drug candidate Aravive-S6 into human clinical testing.

Eck has served a number of global pharmaceutical companies in senior roles, including Eli Lilly and Pfizer, and most recently at Astellas Pharma as vice president of oncology medical sciences.

He said: “I am very excited to be joining Aravive at this point in the company’s development.

"I look forward to helping Aravive realise the full potential that I believe Gas6/AXL inhibition can bring to the treatment of cancer.”

Eck also serves on the board of directors of Texas-based life sciences company Luminex Corporation, he is a fellow of the American Association for the Advancement of Science and is chairman of the board of directors of the Personalised Medicine Coalition.

Ray Tabibiazar, founding president and CEO of Aravive, said: “Stephen has an impressive track-record of oncology drug and biomarker development at prominent pharmaceutical companies, as well as a close relationship to Houston’s M.D Anderson Cancer Centre as a member of the Advisory Board for their oncology Moonshot Programme.

“We welcome his expertise and leadership to the Aravive team.”

Eck succeeds Ray Tabibiazar who will remain as chairman of the company’s board of directors.

12th May 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics